Developmental Research Program

发展研究计划

• 批准号: 10709235
• 负责人: ROBERT C BAST
• 金额: $ 8.52万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-19 至 2028-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10709235
• 关键词: Address; Ally; Area; Award; Basic Science; Budgets; Cancer Center; Clinical; Clinical Investigator; Clinical Research; Collaborations; Data; Dedications; Department of Defense; Development; Discipline; Disease; Early Diagnosis; Early treatment; Financial Support; Foundations; Funding; Funding Mechanisms; Future; Goals; Human; Incidence; Institution; Malignant Neoplasms; Malignant neoplasm of ovary; Manuscripts; Medical center; Ovarian; Peer Review; Population Research; Prevention; Productivity; Program Research Project Grants; Publishing; Quality of life; Research; Research Personnel; Research Project Grants; Resources; Rest; Scientist; Specimen; Texas; Translational Research; University of Texas M D Anderson Cancer Center; Woman; Work; anticancer research; candidate identification; design; improved; innovation; mortality; novel; ovarian cancer prevention; patient population; peer; programs; supportive environment; translational potential; translational study

Developmental Research Program SUMMARY/ABSTRACT The purpose of the Developmental Research Program (DRP) is to fund promising projects by investigators whose current work may not focus exclusively on ovarian cancer, but who propose highly innovative translational studies of ovarian cancer that could become full SPORE projects or compete successfully for funding outside of the SPORE. The DRP provides a unique opportunity for making available significant financial support, and for demonstrating active institutional support, through a program that is rapidly responsiveto new ideas or initiatives. Moreover, this program is rooted in a spirit of collaboration promoted by the SPORE investigators who have an extensive track record of bringing investigators from other disciplines into ovarian cancer research. The strength of the DRP rests in its ability to make available financial support needed to access all the critical expertise and resources within the entire SPORE. This will allow us to develop collaborative, multi-investigator, multi-institutional research projects with the support of innovative, investigator- initiated projects that have the potential to flourish into reliable and productive translational research projects that make a path from basic and/or population research projects into research focused on human clinical specimens/patient populations. Over the course of the past decade, the MD Anderson OvarianSPORE has supported DRP projects from 22 investigators. Collectively, these investigators have published 470 peer- reviewed manuscripts related to ovarian cancer. Thirteen of the recipients have received peer-reviewedfunding in ovarian cancer as either PI, Co-PI or Co-Investigator. The investigators have received funding from three R01s, three R21s, three CPRIT awards, two Department of Defense Awards and four OCRA awards. One awardee in the most recently funded cycle just received support from both the Ovarian Cancer Research Alliance and Foundation for Women’s Cancer. Additionally, three former awardees have participated in full SPORE projects after completing a DRP project.

发展研究计划摘要/摘要 发展研究计划（DRP）的目的是为调查人员提供有希望的项目 目前的工作可能不仅关注卵巢癌，但提出了高度创新的建议 卵巢癌的翻译研究可能成为孢子项目或成功竞争的卵巢癌 孢子外的资金。 DRP为提供大量财务提供了独特的机会 支持，并通过一个迅速做到新的计划来展示积极的机构支持 想法或倡议。此外，该计划植根于孢子促进的协作精神 将其他学科的调查人员带入卵巢的调查人员 癌症研究。 DRP的优势取决于其提供所需的财政支持的能力 访问整个孢子中的所有关键专业知识和资源。这将使我们能够发展 在创新的，研究人员的支持下 发起的项目有可能荧光融合到可靠和产品翻译研究项目中 从基本和/或人口研究项目到研究的研究，这是针对人类临床的研究 标本/患者人群。在过去的十年中，MD Anderson Ovarianspore拥有 支持22位调查人员的DRP项目。总的来说，这些调查人员已经发布了470个同行 审查了与卵巢癌有关的手稿。 13名接收者已收到同行评审筹集 在卵巢癌中为PI，Co-Pi或共同研究剂。调查人员已经从三个 R01，三个R21，三项CPRIT奖，两个国防部奖和四项OCRA奖。一 最近有资助的周期的获奖者刚刚获得了卵巢癌研究联盟和 女性癌症基础。此外，三名前获奖者参加了完整的孢子项目 完成DRP项目后。